http://finance.yahoo.com/news/verisante-technology-inc-announces-exclusive-224809894.html
Verisante Technology, Inc. (VRS.V)(VRSEF)(V3T.F) (the "Company" or "Verisante"), a leader in cancer detection technology, announced today that the Company has entered into an exclusive agreement with BO-Pharma BV to distribute Verisante Aura(TM) in Belgium, the Netherlands and Luxemburg ("Benelux").
"BO-Pharma is the largest independent distributor of medical devices in the Benelux region," said Thomas Braun, President & CEO of Verisante. "With the Benelux market outselling the UK and Germany in some dermatological and skin care devices, our partnership with BO-Pharma provides us a strong foothold in this important region. BO-Pharma will not only distribute Aura(TM), but can also support technical training and servicing in the region."
BO-Pharma and its affiliate, Bo-Esthetics, currently distribute medical devices for skin care treatments, in addition to other devices for use in dermatological practices for a variety of other medical applications. Bo-Esthetics is a leading dermatology distributor in Benelux, distributing the world's top dermatology brands. Aura(TM) is a natural addition to the Company's existing product line.
"Impressive clinical study results show that Aura(TM), through speed and accuracy, is a device that can revolutionize the way skin cancer is diagnosed," said Dr. Henk-Peter Oonk, CEO of BO-Pharma. "The Netherlands has historically been very quick to adopt new, disruptive medical technologies, and we are confident this trend will continue with Aura(TM)."
Last year, Aura(TM) received the Conformite Europeenne (CE) Mark approval, which is recognized by all the 27 Member States of the EU, including Benelux, which has a total population of over 30 million people, and approximately 1,000 dermatologists serving the region. The CE Mark allows the Company to sell Aura(TM) in Europe, a $78 billion medical device market.
Verisante Aura(TM) is indicated for use for the evaluation of skin lesions that may be clinically suspicious for melanoma, squamous cell carcinoma and/or basal cell carcinoma when a medical professional chooses to obtain additional information to rule out one of the above conditions before making a final decision to biopsy. Aura(TM) is a non-invasive optical system that uses Raman spectroscopy to biochemically analyze the skin, providing immediate and accurate results. The device will help to automate the current process of diagnosis, allowing rapid scanning of the 20 to 40 skin lesions on at-risk individuals, improving patient outcomes and comfort.
The European Academy of Dermatology and Venereology (EADV)
Verisante also announced it will be attending the 21st Congress of the EADV in Prague, Czech Republic, from September 27-30, 2012. The Company will be demonstrating a pre-production Aura(TM) device in support of sales and marketing efforts in Europe at our booth (Number 106 on the Third Floor).
About BO-Pharma BV
BO-Pharma BV is a medical device distributor of innovative technology solutions, founded in the Netherlands in 2004. In 2007, BO received a distributors award for fastest sales growth and by 2011 has become the largest independent distributor of medical devices in the Benelux region.
For more information on BO-Pharma BV, visit the Company's websites at http://www.bo-pharma.com/ and http://www.bo-esthetics.com/.
About Verisante Technology, Inc.
Verisante is a medical device company committed to commercializing innovative systems for the early detection of cancer. The Verisante Aura(TM) for skin cancer detection and the Verisante Core(TM) series for lung, colon and cervical cancer detection utilize a proprietary cancer detection platform while the operating software and probe technology are unique to each device. The cancer detection platform was developed by the BC Cancer Agency and tested and refined at the Skin Care Centre at Vancouver General Hospital. This exclusive platform technology allows Verisante to develop and offer a range of compact, non-invasive cancer detection devices that offer physicians immediate results for many of the most common cancers. The Aura(TM) has been approved for sale in Canada, Europe and Australia. The Core(TM) has not yet been approved for sale.
Verisante Aura(TM) was awarded Popular Science Magazine's "Best of What's New Award" for 2011, and Verisante Core(TM) was named one of the top 10 cancer breakthroughs of 2011 by the Canadian Cancer Society. In addition, the Company was named a finalist for the 2011 Regional Awards for New Technology by the Canadian Manufacturers & Exporters and the National Research Council of Canada and named as the year's top ranking Technology and Life Sciences Company on the TSX Venture 50.
Youtube: www.youtube.com/verisante
Twitter: www.twitter.com/verisante
Facebook: www.facebook.com/verisante
Forward Looking Statements
This release contains forward-looking statements, including, but not limited to, statements regarding the future commercialization of medical devices, the market demand for these products and the proprietary protections the Company will obtain with regard to the technology, all of which statements are subject to market risks, and the possibility that the Company will not be able to obtain patent protection or obtain sufficient customer demand. These statements are made based upon current expectations and actual results may differ from those projected due to a number of risks and uncertainties.
The TSX Venture Exchange has neither approved nor disapproved of the contents of this press release. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
Contact:
Thomas Braun
Verisante Technology, Inc.
President & CEO
(604) 605-0507
info@verisante.com
www.verisante.com
Verisante Technology, Inc.
President & CEO
(604) 605-0507
info@verisante.com
www.verisante.com
No comments:
Post a Comment